Revenues for the 3rd quarter 2011

Further growth in activity

STENTYS (FR0000949404 – STNT), a medical technology company commercializing the world’s first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), today reports its third-quarter and nine-month year-to-date revenues until 30 September 2011.

- Quarterly and 9-month revenues

<table>
<thead>
<tr>
<th></th>
<th>YTD 2010 - 9 months</th>
<th>YTD 2011 - 9 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>154.0</td>
<td>970.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Q1 2011 - 3 months</th>
<th>Q2 2011 - 3 months</th>
<th>Q3 2011 - 3 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>251.4</td>
<td>347.6</td>
<td>371.0</td>
</tr>
</tbody>
</table>

* the Company did not draw up quarterly results prior to its IPO, so a comparison with the first half of 2010 cannot be made

Revenues for the 3rd quarter of 2011 totalled €371.0k. The figure is up again compared to the second quarter of 2011, despite the traditional seasonal slowdown of the summer period. For the first 9 months of the year, total sales reached €970k.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, concludes: “Stentys’ self-apposing stents are continuing on a steep adoption curve, confirming the efficiency of the controlled release commercial strategy amongst Europe’s top hospitals. The milestone of a million euros in sales has thus been reached less than 18 months after marketing began. We reiterate our confidence in STENTYS’ continued development, which will be supported by the excellent preliminary results of the APPOSITION III clinical trial announced yesterday.”

- Next press release

STENTYS will publish its 2011 annual revenues on 25 January 2012, after market.

About STENTYS:
Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries. More information on www.stentys.com.

Stentys
Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap.
Financial Communication / Investor & Press Relations
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94

STENTYS is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0000949404 – Ticker: STNT